Which account would you like to be logged in as?

Forgot Password?

Sign Up!

Visa/MasterCard and Discover Users
Flip your credit card over and look at the signature box. You should see either the entire 16-digit credit card number or just the last four digits followed by a special 3-digit code. The 3-digit code is your Card Security Code.

American Express Credit Card Users
Look for the 4-digit code printed on the front of your card just above and to the right of your main credit card number. The 4-digit code is your card Identification Number (CID).

What is a discount code?
Generic discount code text needs to go here

jul 7
Release date

Advances in the Management of Breast Cancer: Highlights from the 2011 ASCO Annual Meeting

Breast Cancer

MEDIA: Newsletter

Estimated time to complete activity: 1.0 hour | Release date: Thursday, July 07, 2011 | Expiration date: Friday, July 06, 2012


Experts from across the globe gathered for the American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, Illinois, June 3-7, 2011. Oncology healthcare professionals learned of the latest innovations in cancer research, quality practice, and future technologies. As evidenced at this year’s meeting, the landscape of cancer treatment continues to evolve. Highlights of this year’s data and research in breast cancer are included in this interactive newsletter.


Primary Prevention of Breast Cancer
HER2+ Neoadjuvant Therapy
HER2+ CNS Disease
Triple-Negative Breast Cancer
Neoadjuvant Bevacizumab
Novel Therapeutic Mechanisms


Joyce O'Shaughnessy, MD

Co-Chair, Breast Cancer Research Program
Celebrating Women Chair in Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
US Oncology
Dallas, Texas

Christy A. Russell, MD

Associate Professor of Medicine
Co-Director, University of Southern California
Norris Breast Center
University of Southern California
Los Angeles, California


The intended audience for this initiative is medical, surgical, and radiation oncologists, and oncology specialty pharmacists, charged with the care of patients with breast cancer.


At the conclusion of this activity, participants should be able to:

  • Summarize the efficacy and safety results from key trials introducing use of novel agents and/or mechanisms
  • Select appropriate chemotherapy/biologic combination regimens based on current understanding of clinical markers, efficacy, and safety profiles
  • Describe advances in the development and integration of biologic therapies for the management of patients with breast cancer in novel disease settings and combinations
  • Evaluate emerging new therapeutic options for treatment of breast cancer by reviewing ongoing and planned clinical trials


Accreditation Statement
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Educational Concepts Group, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ACPE Logo Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

Educational Concepts Group, LLC designates this continuing education activity for 1.0 contact hour (0.10 CEU) (UAN 0199-0000-11-023-H01-P).

Type of activity: Knowledge-based


There are no fees for participating and receiving CME/CE credit for this activity. During the period Thursday, July 07, 2011 through Friday, July 06, 2012, participants must 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.


Physicians and pharmacists who complete the post-activity assessment with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.


It is the policy of ECG that the faculty, authors, planners, and other persons who may influence content of this CME/CE activity disclose all relevant financial relationships with commercial interests in order to allow ECG to identify and resolve any potential conflicts of interest.

The Following Faculty Members Have Declared Relevant Financial Relationships

Joyce O'Shaughnessy, MD Honorarium

Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Caris Life Sciences, Inc.
Eisai Inc.
GTx, Inc.
Johnson & Johnson

Speakers’ Bureau Celgene Corporation

Christy A. Russell, MD Honorarium AstraZeneca
Genomic Health, Inc.
Speakers’ Bureau AstraZeneca
Genomic Health, Inc.

Staff Disclosure
Planners and managers at ECG have no relevant financial relationships to disclose.


The editors wish to thank Maureen Haas, PharmD, BCPS, BCOP, for assistance in writing this document.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.


This activity is supported by educational grants from the following: Celgene Corporation, Genentech, Merck & Co., Inc.


For further information, please contact:
Educational Concepts Group, LLC
1300 Parkwood Circle SE, Suite 325
Atlanta, Georgia 30339
Phone: 1.866.933.1681
Fax: 1.866.933.1692

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.

Yes, I have read the information above and am interested in participating.